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Background: The incidence of age-related cognitive decline is rising considerably around the world. There is evidence
from a number of recent cross-sectional and prospective studies indicating positive associations between the
Mediterranean dietary pattern (MedDiet) and improved cognitive outcomes among the elderly including, reduced
age-related cognitive decline and enhanced age-related cognitive performance. However, to date no study has
validated these associations in healthy older adult populations (≥65 years and above) with randomised evidence. The
main aim of the present study is to provide justified evidence regarding the efficacy of a MedDiet approach to safely
reduce the onset of cognitive decline, and promote optimal cognitive performance among healthy older adults using
rigorous, randomised intervention methodology.
Methods/Design: MedLey is a 6-month, randomised controlled 2-cohort parallel group intervention trial, with initial
assessment at baseline and repeated every three months. A sample of 166 healthy Australian men and women aged
65 years and above, with normal cognitive function and proficient in English language were recruited from
metropolitan Adelaide, South Australia for the study. Participants randomly allocated to the experimental group are
required to maintain an intervention dietary pattern based from the traditional Cretan MedDiet (i.e. vegetables, fruits, olive
oil, legumes, fish, whole grain cereals, nuts and seeds and low consumption of processed foods, dairy products, red meat
and vegetable oils) for six months, while those participants allocated to the control group are asked to maintain their
customary lifestyle and diet. The primary outcome of interest is the quantitative difference in age-related cognitive
performance, as measured by latent variables (cognitive constructs) sensitive to normal ageing and diet (i.e. speed of
processing, memory, attention, executive functions, visual spatial and visuomotor ability). Secondary outcomes include
change in biomarkers of inflammation, oxidative stress, lipid metabolism, glucose, insulin, blood flow velocity, and
psychological well-being factors (i.e. stress, sleep, anxiety, depression).
Discussion: To our knowledge this will be one of the first randomised clinical trials worldwide to provide evidence for
the cause-effect relationship between the MedDiet and age-related cognitive function in a healthy older adult
population (≥65 years and over).
Trial registration: Australia and New Zealand Clinical Trials Register (ANZCTR): ACTRN12613000602729.
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Age-related cognitive decline is rising as one of the
world’s most detrimental health problems as the popu-
lation ages. Although cognitive deterioration is consid-
ered an inevitable part of ageing, the rate and severity of
cognitive decline is not homogenous among all individ-
uals, ranging from normal age-related change, to mild
cognitive impairment (MCI), to chronic neurodegenera-
tive disease (e.g. dementia, Alzheimer’s disease [AD],
Parkinson’s disease) [1]. Of utmost concern is the fact
that pathological brain disorders such as AD are pres-
ently considered incurable, with no current lasting
pharmaceutical treatment options that are effective in
stopping or reversing the progression of disease. The ef-
ficacy of current treatments available (e.g. donepezil,
galantamine, rivastigmine), at most, offer minor symp-
tomatic relief for AD sufferers [2].
Recent evidence has provided emerging insight into
modifiable lifestyle factors, such as diet, that may have
an effect on slowing the onset and/or progression of
age-related cognitive decline and promoting healthy cog-
nitive ageing. In particular, the Mediterranean dietary
pattern (MedDiet), rich in bioactive phytochemicals (e.g.
constituents of olive oil, red wine, green leafy vegetables,
fish, walnuts and seeds, such as antioxidants, fibre, vita-
mins, minerals, omega-3 fatty acids and monounsatu-
rated fat), and low in red meat, dairy products and
processed foods, is leading the interest of researchers
and the general public. In fact, an accumulating number
of empirical studies [3-5], including a recent systematic
review [6] have shown preliminary evidence for the effi-
cacy of MedDiet intake on a range of age-related cogni-
tive outcomes. Collectively, such evidence indicates
therapeutic potential for a MedDiet intervention to as-
sist in protecting and preserving normal cognitive func-
tion in older age through slowing down the progression
of cognitive decline and reducing risk of developing neu-
rodegenerative pathologies [7].
The MedDiet approach to preserving better cognitive
health in older age may be attractive to older adults, and
also various governmental health agencies for a number of
reasons. Firstly, the MedDiet is proposed as a potentially
“natural” approach to reduce the onset of cognitive de-
cline and prevent chronic neurological disorders (e.g. AD),
as opposed to the alternative pharmaceutical approach.
Improving cognitive function, life expectancy and overall
health and well-being through diet and lifestyle modifica-
tions, may be a more favourable option for the elderly
than using more stringent pharmacological alternatives.
Indeed, many pharmacological treatments have associated
side effects that can be quite adverse for this population
[2]. Secondly, with reduced prevalence of these disorders,
it is likely there will be a subsequent reduction in associ-
ated socio-economic and disability burdens as well.Cross-sectional and prospective studies
A growing body of cross-sectional and prospective studies
have found higher adherence to a MedDiet pattern is
associated with improvements in a range of cognitive out-
comes for healthy older adult populations including:
slower global cognitive decline [5,8,9], higher episodic
memory [5], global cognitive performance [10-15], higher
verbal memory performance [14], even after adjustments
for cofounds. In addition, a number of studies [16-18]
have shown evidence for these associations among non-
clinical populations.
Although these findings appear encouraging, some
studies report no beneficial effect of the MedDiet on
age-related cognitive outcomes for healthy older indi-
viduals [19,20]. Thus, the question of whether adher-
ence to a Mediterranean dietary pattern is beneficial to
the normal (i.e. non-pathological) ageing brain remains
equivocal at present.
Randomised controlled trials
Without question, the only way of validating the effi-
cacy of the MedDiet as a preventative approach for
older adults will rest upon evidence from randomised
controlled intervention trials (RCTs). However, to our
knowledge, there has only been one published RCT on
cognitive ageing outcomes among the elderly to date.
Martínez-Lapiscina and colleagues [3] conducted a 6.5 year
RCT in Spain, investigating the effects of a MedDiet inter-
vention on global cognitive performance among 522
elderly participants at high risk of cardiovascular disease
(i.e. had to be carrying the presence of type-2 diabetes,
or at least 3 major risk factors hypertension, dyslipid-
emia, smoking and obesity). In a parallel-group, cardio-
vascular prevention trial, participants were randomised
to either a MedDiet supplemented with extra virgin
olive oil (EVOO), a MedDiet supplemented with mixed
nuts, or a low-fat control diet, and assessed on global
cognitive functioning using the Mini-Mental State
Examination (MMSE) [21] and a Spanish version of the
Clock Drawing Test (CDT) [22]. After 6.5 years of diet-
ary intervention follow-up, results of this trial indicated
that mean MMSE and CDT scores were significantly
higher for participants allocated to a MedDiet pattern
supplemented with either EVOO or mixed nuts, com-
pared with the control group. This finding provides fur-
ther support to the hypothesised benefit of MedDiet
intake on age-related cognition.
However, the evidence generated by this study is re-
stricted to a specific population (i.e. older adults at high
cardiovascular risk), and the results may not be general-
isable to the wider elderly adult population. The range
of cognitive tests utilised in the study was restricted,
preventing a clear delineation of those specific aspects
of cognition assisted through the dietary intervention.
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and range of cognitive functions critically impacted (e.g.
speed of processing, executive functioning, attention) and
how these relate to changing biological and neurological
functioning. This is an important gap to address in future
RCTs because conclusions about the efficacy of a MedDiet
pattern on change in age-related cognitive function cannot
advance without generating a clearer understanding of
how individual aspects of cognition, across all domains,
are influenced by MedDiet intake during the normal age-
ing process [23].
Underlying mechanisms of the Mediterranean dietary
pattern on age-related cognition
To date, no clear mechanistic explanation has been docu-
mented regarding the inferred relationship between Med-
Diet intake and improved age-related cognitive function.
However, preliminary evidence from prior observational
studies has begun to shed some light on potential under-
lying factors that may be involved. Indeed, certain individ-
ual foods and their constituents found in the MedDiet
pattern (i.e. vitamins E, B6, B12, folate, monounsaturated
fatty acids, fish, carotenoids, flavonoids, omega-3 and
omega-6 polyunsaturated fatty acids and antioxidants)
may be protective against the development of cognitive
decline [24-26] possibly through a direct effect on brain
physiology. When these foods and constituents are com-
bined, it is assumed that the interrelated actions of a
whole dietary pattern may generate even more powerful
synergistic, additive or antagonist actions in the brain that
single food factors are unable to achieve.
A second line of reasoning suggests biological mecha-
nisms could also be implicated as underlying factors. In-
deed, a growing body of studies have documented strong
evidence showing the effect of nutrition on cardiovascular
health, including the positive effect of the traditional Med-
Diet [27], and conversely, the inverse effect of the typical
Western diet [28,29]. Of particular note, specific biological
mechanisms such as oxidative stress, inflammation, insu-
lin resistance and reduced cerebral blood flow have indi-
vidually been postulated as key factors in the pathogenesis
of both normal cognitive ageing and chronic neurodegen-
erative change [8,30-32].
Evidence that the MedDiet may reduce the risk of unsafe
levels of these biological markers in the brain have been
found in a number of recent studies. For example, Gu and
colleagues [10] showed that adherence to a MedDiet pat-
tern reduced inflammation markers C-reactive protein
(hsCRP) and interleukin-6 levels. Similarly, the MedDiet
has also been found to reduce oxidative damage [33],
which may affect the physiology of the ageing brain dir-
ectly, by protecting neuronal and cell-signalling function
and maintenance. Other recent studies have shown bene-
fits of MedDiet adherence on endothelial function. Sorondand colleagues [34] found that consumption of a flavonol-
rich cocoa drink for two weeks significantly increased cere-
bral blood flow velocity among healthy older adults. Given
that the MedDiet is particularly rich in flavonoids, there is
a potential for similar effects to occur in the brain, improv-
ing blood flow and overall endothelial function [35].
Taken together, we propose the underlying mechanisms
of the MedDiet pattern on age-related cognitive health
may be multifactorial, with associations between MedDiet
food components, cardiovascular risk factors, and age-
related cognitive function. In turn, this complex event may
generate either direct effects on brain physiology at the
neuronal and cellular level, or influence cognitive function
more indirectly through improved cardiovascular health.
Methods
The Mediterranean diet for cognitive function and cardio-
vascular health in the elderly (MedLey) study is investigating
a wide array of outcomes relating to age-related cognitive
performance, cardiometabolic health, psychological well-
being and genome health. The current paper provides a
comprehensive synopsis for the main design of the MedLey
trial, including ethics approval, participant recruitment,
screening and selection, randomisation, study procedure,
safety considerations, and focuses on the rationale and
methodology for the cognitive outcomes of interest.
Ethics
Ethical approval was given by the University of South
Australia Human Research Ethics Committee, and the
Flinders University Southern Adelaide Clinical Human Re-
search Ethics Committee (ID:31163). The trial was success-
fully registered in the Australian New Zealand Clinical
Trials Registry (ACTRN12613000636752), and adheres to
the principles of the Australian Code for the Responsible
Conduct of Research.
Objectives for cognitive outcomes
The primary aim of the MedLey trial in relation to the cog-
nitive outcomes was to comprehensively examine, over six
months, the effects of a MedDiet pattern on age-related
cognitive performance, specifically, speed of processing,
memory, attention, executive functions, visual spatial and
visuomotor ability. It was hypothesised that among a sam-
ple of non-demented, male and female Australian older
adults aged 65 years and above, the MedDiet group would
show significantly greater age-related cognitive perform-
ance in aspects of fluid cognitive ability when compared
with the habitual dietary control group over six months.
Secondary aims were: 1. to explore whether the effect of
MedDiet intake on age-related cognitive functioning is
mediated by hsCRP (biomarker of inflammation), F2-
isoprostanes (biomarker of oxidative stress in vivo), meta-
bolic biomarkers (lipids, glucose, insulin), and blood flow
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mine whether psychological well-being factors (stress,
sleep, anxiety, depression) moderate the strength of
association between MedDiet intake and age-related
cognitive performance.Study design
The MedLey study is a 6-month, randomised, controlled,
2-cohort parallel group comparison intervention trial,
with repeated measures every three months, over three
time points, to assess the effects of a MedDiet pattern
with a habitual Western dietary pattern on age-related
cognitive performance and cardiometabolic health. Due
to the sheer extremity and length of the assessment
process, a rolling recruitment was used over two cohortsFigure 1 Flow diagram of the overall study design for the MedLey trial.(i.e. first cohort from June to September 2013, second
from March to May 2014). Both cohort 1 and cohort 2
involved equivalent methods of recruitment, screening,
assessment, and the same dietitians and researchers con-
ducting the assessments and dietary consultations.
Hence, collectively, the total study length of the trial in-
volving the two cohorts was approximately 18 months in
total. In accordance with the CONSORT statement [36],
a flow diagram of participants intended progress
throughout the intervention trial is documented (see
Figure 1).Participant recruitment
Based on power and sample size calculations (see Power
below), an initial sample of 166 healthy Australian men
Knight et al. BMC Geriatrics  (2015) 15:55 Page 5 of 14and women aged 65 years and above, with normal cogni-
tive function and proficient in English language, were re-
cruited from metropolitan Adelaide, South Australia
through response to public advertisements in local broad-
cast and print (i.e. newspapers, magazines) media, posters,
flyers and also presentations from our researchers at local
senior groups and clubs. Participation in the MedLey trial
was entirely voluntary, and participants were informed they
were free to withdraw at any stage during the trial. Partici-
pants were provided with an honorarium of $100, to reim-
burse for study related expenses (e.g. parking fees).Participant screening and selection
Volunteers who expressed interested and responded to the
study advertisements were sent an information pack and
questionnaires to collect further information regarding
their general health and medical history. The information
pack included the following: a cover letter, participant in-
formation sheet including any risks associated with partici-
pation in the study, a pre-screening diet and lifestyle
questionnaire (DLQ), map, and also a reply paid envelope.
Upon receipt of volunteers returned, completed DLQ
questionnaire, if they appeared to be eligible by the study
investigators, they were invited to attend the Sansom Clin-
ical Trials Facility at the University of South Australia for a
screening visit.
The initial screening visit was used as a way to ensure
that only volunteers who met the full inclusion criteria
were included in the study. At this visit, volunteers signed
a consent form and then subsequently had their weight,
height and blood pressure measured, as well as providing a
fasting blood sample for a full blood examination includ-
ing: liver function, blood lipids, and glucose to ensure there
were no underlying health concerns. Screening blood sam-
ples were analysed by SA Pathology, a National Association
of Testing Authorities (NATA) accredited pathology.
As the population of interest for the MedLey RCT was
healthy older adults (≥65 years), it was imperative to screen
for MCI and dementia. A validated screening instrument;
the DemTect [37] was chosen for this purpose. The Dem-
Tect includes five subtests: 1. a word list task to assess im-
mediate and delayed recall, 2. a number transcending task,
where participants translate numerals to number words
and vice-versa (e.g. 100 to one hundred) to assess language,
3. a semantic verbal fluency task [items found in a super-
market task], and 4. a digit span task to assess working
memory). Together, these subtests cover a diverse assess-
ment of particular cognitive functions known to be sensi-
tive to MCI and dementia, with high sensitivity in
detecting early AD (sensitivity of 100%) and also in detect-
ing MCI (sensitivity of 80%). Furthermore, the DemTect
has been found to have high construct validity, inter-rater
and test-retest reliability [37].Scoring of the DemTect followed the standard protocol
outlined by Kalbe and colleagues [37]. Firstly, each of the
five subtest raw scores were adjusted for age and educa-
tion. Subsequently, the five transformed subtest scores
were summed together to provide an overall DemTect
score for each participant, which was classified as either:
‘appropriate for their age’ (score 13–18), ‘mild cognitive im-
pairment’ (score 9–12), or ‘suspected dementia’ (score ≤8).
Those volunteers with scores <13 on the DemTect, indicat-
ing possible dementia, were kindly referred to a local gen-
eral practitioner by one of the senior researchers.
Potential volunteers were invited to participate in the
six month MedLey RCT if they met the following cri-
teria: considered a free-living Australian man or woman
aged 65 years and above, obtained a DemTect score ≥13
(no present dementia, healthy age-related cognitive func-
tion), and were proficient in English language. Partici-
pants were excluded from entry to the study if they
scored an age adjusted score of <13 on the DemTect,
had experienced any of the following conditions previ-
ously or currently which may cause some form of cogni-
tive impairment, including a stroke, traumatic head/
brain injury, or suffer a neurological or psychiatric con-
dition, were using medications known to influence cog-
nition, had current cardiovascular disease or angina,
uncontrolled hypertension (>170/100), current or recent
(in the last 6 months) malignancy, major liver, kidney,
respiratory, gastrointestinal disease, a weight of ≥135 kg,
were actively undertaking a weight loss program, using
any form of appetite suppressant or Orlistat (Xenical),
smoked, were already participating in another dietary
intervention study, were vegetarian, and finally deemed
by the investigator to be unwilling, unlikely or unable to
comprehend or comply with the study protocol.Participant randomisation
Participants were de-identified according to gender,
age and body mass index (BMI) and randomly allo-
cated by a process of minimisation to one of two diet-
ary groups Group 1. Mediterranean Diet experimental
group (n = 85); Group 2. Habitual Diet, control group
(n = 81). The two groups were then split into four
groups comprising of two experimental and two con-
trol groups, with one experimental and one control
group allocated to either cohort 1 or cohort 2 accord-
ing to the preference and availability of the partici-
pants. Randomisation was performed by one of the
chief investigators, who was not directly involved with
study participants during data collection or data ana-
lysis. The researcher who administered the cognitive
test battery and assessed and scored cognitive out-
comes was blind to group assignment and will remain
blind until after data analysis to reduce bias.
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Following the results of the initial screening visit, those
volunteers who were eligible to take part were notified of
their eligibility and invited to participate in the study.
Upon a signed declaration confirming consent, by the
end of the trial, participants will have been assessed at three
time points at the Alliance for Research in Exercise, Nutri-
tion and Activity (ARENA) at the University of South
Australia for the evaluation of age-related cognitive func-
tion and cardiometabolic outcomes (see Table 1).Visit 1a, 2a, 3a (baseline, 3 months, 6 month)
Following an overnight fast, participants attend the
ARENA on two morning visits (Visit a and Visit b),
spaced one week apart, for assessments at baseline, three
months and six months. On the first of the two week as-
sessment visits (Visit a) participants commence a seriesTable 1 Measurements for all outcomes of interest (cognitive
undertaken at each study time-point
Assessment 0 months 3
Blood sample ✓ ✓
Height ✓
Weight ✓ ✓
Cognitive function/psychological wellbeing ✓ ✓
Waist circumference ✓ ✓
Blood pressure and heart rate ✓ ✓
Body composition and bone mineral density (DEXA) ✓ ✓
Blood lipids ✓ ✓
hs-CRP ✓ ✓
Insulin & glucose ✓ ✓









Telomere length (qPCR) ✓
Mitochondrial DNA deletions (qPCR) ✓
DNA base oxidation (qPCR) ✓
APOε4 genotype ✓
Plasma oxidised and reduced glutathione ✓
Micronucleus index (Cytokinesis-block ✓
micronucleus cytome [CBMNcyt] assay) ✓of cardiometabolic measurements including: a collected
40 mL blood sample for the determination of glucose,
insulin, hs-CRP, triglycerides, HDL-C, total cholesterol,
F2-isoprostanes (PGF2α), erythrocyte fatty acids and
plasma carotenoids, 5 mL saliva and buccal cells col-
lected from both cheeks using a tooth brush for deter-
mination of DNA biomarkers, measurements of blood
pressure and assessment of cerebral vasodilator re-
sponses (TCD) and endothelial vasodilatory function
(FMD) (see Table 1).
In addition, on Visit (a), participants undergo neuro-
psychological assessment for the evaluation of age-related
cognitive function. In this session, a battery of 13 cognitive
tests are administered to participants individually, which
takes approximately 1.5 hours to complete (see Cognitive
Measures below). Tests are presented to each participant
in the same order on each of their testing visits, along with
standardised instructions. To reduce the possibility ofand cardiovascular) investigated in the MedLey trial,



















✓ Half from cohort 1, all from cohort 2
✓ 20 males, 20 females
✓ 20 males, 20 females
✓ 20 males, 20 females
✓ 20 males, 20 females
✓ 20 males, 20 females
✓ 20 males, 20 females
✓ 20 males, 20 females
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terbalanced across participants. Scoring of cognitive tests
has been performed by the same researcher for all partici-
pants to reduce experimenter bias.
At the very end of Visit (a), participants are issued with a
brown carry bag containing the following items to take
home and complete during the following week: 1. blood
pressure monitor to measure blood pressure at set inter-
vals each day over the following week; 2. of a detailed, three
day weighed food record (WFR), a food frequency ques-
tionnaire (FFQ) are used for the evaluation of habitual diet-
ary intake consumed over the past 12 months 3. a large
bottle and cup to collect a 24 hour urine sample; 4. a psy-
chological well-being pack containing a series of question-
naires to evaluate level of depression, trait and state
anxiety, stress and sleep quality (see Psychological Well-
being Measures below). Explicit instructions are given to
participants both in person and in a take home booklet to
ensure assessment items are correctly administered and
data is accurately recorded. Finally, at the completion of
the session, participants are provided with complimentary
breakfast.
Finally, from the mid-way point through baseline of
cohort one and thereafter throughout the trial, the Food
Cravings Inventory (FCI) (altered and approved protocol
amendment) is administered at baseline, 3 months and 6
months to assess participants experience with food crav-
ings and whether or not they are changing throughout
the duration of the RCT.
Visit 1b, 2b, 3b (baseline, 3 months, 6 month)
One week after Visit 1a, 2a, 3a, volunteers return to the
ARENA centre for a second morning appointment
(Visit 1b, 2b, 3b) after an overnight fast. Participants
undergo assessments in height, weight, BMI, waist and
hip circumference, and then complete a Dual X-ray Ab-
sorptiometry (DEXA) assessment, performed using a
Lunar Prodigy DEXA machine by qualified investigators,
to measure body composition, specifically precent of
body fat. Participants are made fully aware of any poten-
tial risks associated with radiation exposure, and then
asked to sign a consent form if they understand such
risk, and are happy to proceed. Following obtained con-
sent, participants are instructed to remove their outer
clothing, jewellery, watches, and any other metal objects
before lying in the supine position on the DEXA bed for
the duration of the scan. After the DEXA scan is com-
pleted, participants are provide with a complimentary
breakfast.
Following breakfast, participants meet with a qualified
dietitian. On the first Visit (b) assessment appointment
(Visit 1b), participants are informed which experimental
dietary condition they were assigned to (i.e. MedDiet;
experimental or HabDiet; control), and thereafter receivedetailed instructions regarding their meal plan for the
next 6 months. The meal plan for those participants ran-
domised to the MedDiet is tailored specifically for each
participant based on their individual tastes, preferences
and energy requirements (see Experimental Diet below).
To assist with making Mediterranean food choices
which meet the specific guidelines of the MedDiet, par-
ticipants are also issued with recipe books, menu guides
and sample menus. Alternatively, those participants ran-
domised to the HabDiet control group were asked to
maintain their usual dietary and exercise pattern for
6 months.
Fortnightly visits with the dietitians are administer for
all participants regardless of allocated diet group, to
provide the opportunity to discuss any issues, questions,
or receive further advice regarding their allocated diet.
At week nineteen fortnightly visit for participants in co-
hort one, and week 5 for those in cohort two, a Lifetime
Diet Questionnaire (LDQ) is administered to gather in-
formation about participants diet across the lifespan
and whether there were differing or similar foods con-
sumed during the different periods of their life.
Safety considerations
The safety of participants is foremost, and ensured via
procedures to minimise the risk of any harm in the form
of physical pain or discomfort, emotional or psycho-
logical distress from either blood taking techniques, car-
diometabolic measures, or cognitive testing. Should an
adverse event arise due to participation in the trial it is
treated immediately by trained ARENA staff where pos-
sible, with appropriate referrals provided and arranged
for participants if needed. Blood samples are taken by
ARENA staff and students trained and proficient in
phlebotomy. This is done according to the ARENA
standard operating procedure using aseptic techniques
to minimise risk of infection to volunteers and injury to
staff. All adverse events are reported in Case Report
Form files, reported to the University of South Australia
Human Research Ethics Committee at the time of the
event, and followed up by the researchers.
Measures
Demographic information
Demographic information including: participant’s gender,
age, self-rated physical, mental and social health status,
marital status, highest level of education achieved, coun-
try of birth, parents’ country of birth, current occupation
and level of work, income level, and perceived adequacy
with current income level, family history of diagnosed
chronic health conditions and diseases, including de-
mentia, current medications, and vitamin supplements
were gathered from participants for the ability to control
for confounding variables.
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Experimental diet - Mediterranean dietary pattern (MedDiet)
The Mediterranean style dietary pattern that was devel-
oped and used for the MedLey RCT, was based from the
traditional Cretan MedDiet developed by Trichopoulou
and colleagues [38], as well as the MedDiet food pyramids
developed by Kromhout et al. [39] and Willett and col-
leagues [40]. In light of these literature sources, the key
food and nutrient characteristics of the traditional Cretan
Mediterranean dietary pattern (i.e. vegetables, fruits, olive
oil, legumes, fish, whole grain cereals, nuts and seeds;
moderate red wine, and low consumption of processed
foods, dairy products, red meat and vegetable oils) were
adopted as the primary foundation of the MedDiet. The
approximate nutrient targets for per cent fat as monoun-
saturated fat, monounsaturated to saturated fat ratio, fibre,
total contributions to energy from fat, saturated fat and
carbohydrate and vitamin C, folate, and magnesium have
been obtained from these sources, and are roughly in ac-
cordance with previous dietary intervention trials investi-
gating the MedDiet [41,42].
Throughout the duration of the intervention, participants
who were allocated to the MedDiet group received sufficient
food, provided in appropriate cooler bags for transport,
which incorporated 30-35% of the total energy provided by
their allocated diet. Such foods included: Legumes
(chickpeas, lentils, four-bean mix) (kindly donated by
Simplot Australia Pty. Ltd), yoghurt (natural/flavoured
Greek), Australian extra virgin olive oil (kindly donated by
Cobram Estate), canned tuna (kindly donated by Simplot
Australia Pty. Ltd.), walnuts, almonds (kindly donated by
The Almond Board of Australia) and peanuts (kindly do-
nated by the Peanut Company of Australia).Control diet - Australian habitual dietary pattern (HabDiet)
Participants randomly allocated to the control group
(HabDiet) are asked to maintain their usual lifestyle and
dietary pattern. To reduce bias, on a fortnightly basis, they
are also required to attend the ARENA clinic to meet with
the dietitian to have their weight measured, discuss any
changes in medication and any issues that may have arose.
Volunteers are provided with either a food voucher for
their supermarket of choice, or sufficient food provided
throughout the intervention trial, that account for around
20-30% of their estimated energy requirements in the
form of dietary staples, including: canola oil (kindly
donated by Goodman Fielder Ltd), bread, milk and yogurt
if it is part of their habitual diet.Compliance
Compliance is measured via four means of assessment,
1. a semi-quantitative daily food check list, 2. the food
frequency questionnaire (FFQ; Cancer Council Victoria), 3.the 3-day WRF's, 4. red blood cell fatty acid RBCFA compos-
ition (i.e. marker of fat intake which will be important given
changes in saturated fat/monounsaturated fat intake), 5.
plasma carotenoids (CRTs) via a blood sample, as biomarkers
of fruit and vegetable intake, and 6, urinary metabolites. Par-
ticipants are assessed on all means of compliance at each as-
sessment time-point to ensure a high level of compliance is
met. Furthermore, participants are continually instructed and
monitored by the fully qualified dietitians on the trial each
fortnight to make certain compliance is followed accordingly.
Cognitive measures
The neuropsychological test battery for the MedLey RCT
includes a series of individual cognitive measures to assess
a diverse range of particular cognitive functions sensitive to
normal age-related effects, and also likely to be affected by
dietary factors. All included tests are administered via a
paper- and -pencil format, in a private room, with only one
participant and the examiner at any given time. The ration-
ale for the selected test battery was based on sensitivity to
ageing with healthy older adult populations (65–90 years),
and hypothesized effects on the brain. Furthermore, in an
attempt to achieve the highest standard of psychometric
quality possible, the range of cognitive measures chosen for
the MedLey RCT were selected using a highly authoritative
taxonomy of cognitive measures by Lezak [43].
Executive function
Interference control
Dodrill’s [44] version of the Stroop Test is used to assess
participant’s level of interference control (i.e. cognitive
form of inhibition and selective attention). This version
of the Stroop Test consists of two alternate trials using
one stimulus card that contains a list of 176 colour
words printed in incongruous ink (e.g. the word “blue”
printed in yellow ink), and randomly ordered. In the first
trial participants are asked to read the words while ig-
noring the colours they are printed in, as quickly as they
can, going across the page line by line. In the second
trial, participants are asked to name the colours in which
the words are printed while ignoring the words them-
selves. Scores are based on the time taken to complete
each task, and also the time taken to reach the half way
point. As standard, two performance scores are gener-
ated for the Stroop Test; the time taken to complete
each trial. From these scores, an interference score is
then calculated, which represents the ratio of the time
taken to name colours divided by the time taken to read
words. Higher scores reflect higher levels of interference
and therefore poorer performance. The additional time
taken to perform the second subtask compared with the
first subtask is commonly referred to as the “Stroop
interference effect”, and reflects an individual’s degree of
interference control. In addition, the number of
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ticipant is also collected for the ability to assess the se-
verity of impaired performance on this test [45]. The
Stroop interference score has been found to correlate
moderately well with other measures of attention involv-
ing continuous performance tasks (R2 = .310 [46], pro-
viding evidence for construct validity. Furthermore,
good test-retest reliability (r = .90) has been documented
for this version [47]. Alternate forms of this test was
used and counterbalanced across participants over the
three treatment arms to reduce potential practice effects.
Strategic retrieval search
Two measures of verbal fluency, namely the Initial Letter
Fluency (ILF) and the Excluded Letter Fluency (ELF) tests,
are administered. In the ILF [43] participants are asked to
produce as many words beginning with a particular letter
as quickly as they can in 60 seconds, without using words
that begin with a capital letter for a brand, place or person
(e.g. for the letter C “Canberra or Christine”), words that
are numbers (e.g. “eight”), or the same word that ends with
a different ending (e.g. “catch, catching”). Finally, partici-
pants must name words that contain more than three let-
ters. Participants are asked to repeat this process for two
letters (for F and then for S) or (L and C, alternate form),
on two separate 60 second trials. A total ILF performance
score on this task represents the number of words correctly
produced across the two trials, summed together. Bryan
and colleagues [48] found a moderate alternate form reli-
ability coefficient (r = .72) for the ILF test. In the ELF, par-
ticipants were asked to produce as many words as possible
that do not contain the letter E (on the first trial, or R, alter-
nate form), and then not containing the letter A (on the
second trial, or T, alternate form). Scores on both trials
were then summed together to produce an overall ELF
score. Evidence for moderate alternate form reliability for
the ELF (r= .61) was found by Bryan et al. [48]. Alternate
forms of both the ILF and the ELF were used and counter-
balanced across participants over the three treatment arms.
Planning
D-KEFS [49] version of the Tower of London (TOL) test is
used to measure executive functions, particularly spatial
planning (i.e. the ability to problem solve in a way that in-
volves mentally visualizing the outcome prior to physically
carrying out the action) [49], as well as inhibition and rule
learning. In a series of nine different problems, participants
are asked to move a set of five disks from a starting config-
uration, which has three vertical pegs on top of a wooden
platform. The aim is to move the set of disks to the speci-
fied goal configuration in the least number of moves pos-
sible, while overcoming two specific restrictions (i.e. a
larger disk may not be placed on top of a smaller disk and
only one disk can be moved at a time). Scores on the TOLrepresent the total number of permitted moves made
across all the items relative to the minimum number of
moves required to solve the problems, the number of viola-
tions (i.e. illegal moves) made, and also the total time taken
to complete the tasks, which provides an index of an indi-
vidual’s spatial planning ability, and learning strategy ability.
Taken together, fewer moves used to successfully construct
the towers of items 1 through to 9, and less time taken, rep-
resents greater executive functioning ability. High internal
consistency for The D-KEFS Tower Test among older
adults has been found by Delis, Kaplan and Kramer [49],
with intercorrelations between test items ranging from .61
to .72.
Memory
Episodic recall and recognition
Rey and Schmidt’s [50] Rey Auditory Verbal Learning Test
(RAVLT) is used to assess episodic verbal recall and recog-
nition. In the first trial, the examiner reads a list of 15
words (List A) at a rate of one word per second and asks
the participant to repeat back as many words as they can
remember, in any order. The examiner then reads the same
list of 15 words aloud and asks the participant to again re-
call the list of words. This process continues for trials 3, 4
and 5. In trial six, the examiner reads aloud a second list of
15 different words (List B), and asks the participant to re-
peat back as many words as they can remember. Immedi-
ately after recall of List B, participants are then asked to
recall as many words from List A as they can remember. In
trial seven, following a 20 minute delay, the examiner then
asks the participant to recall as many words as they can re-
member from List A. Finally, the participant is shown an
A4 sheet of printed words that contained a total of 30
words from both List A and B, as well as 20 distracter
words not appearing in either list. They are then asked to
circle the words they identified as being read aloud, and
also indicate whether they were from the first or second list
of words by placing a “1” or “2’ next to the words they have
circled. RAVLT performance scores consisted of the sum of
words recalled from the five trials of List A, words recalled
after a delay, and those recognised. The validity of the
RAVLT in identifying memory impairment has been shown
by Tierney and colleagues [51] who found healthy elderly
participants performed significantly better on all measures
of the RAVLT compared with demented patients with ei-
ther Parkinson’s disease or Alzheimer’s disease. Evidence
for good test-retest reliability for the RAVLT has been
found by Knight, McMahon, Green and Skeaff [52]. Alter-
nate forms of RAVLT (A, B and C) was used and counter-
balanced across participants over the three treatment arms.
Short-term memory and working memory
The Digit Span Forward (DSF), Digit Span Backward (DSB)
and the Letter-Number sequencing (LNS) subtest tasks
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Scale (WAIS-IV) [53], are used to measure short term
memory (DSF) and working memory (DSB and LNS). For
DSF, participants are read a consecutive string of numbers
(from 1–9) at a rate of one per second, and asked to repeat
them back in the exact order they are presented. For the
DSB task, participants are asked to repeat the sequence of
numbers back in the exact reverse order that they were pre-
sented. String lengths range from two to eight digits and
each trial presented two lists of the same string length. For
each one of the eight trails over the two Digit Span tasks, a
score of zero is given if a participant makes an incorrect re-
sponse, and a score of 1 was given for a correct response.
Individual total raw scores for the DSF and DSB tasks is
calculated by summing the accumulated scores for the eight
trials administered to each separate task. The maximum
total raw score for both the DSF and the DSB was 16.
For the LNS task, participants are presented with strings
of numbers and letters at a rate of one item per second,
and afterwards asked to repeat back the numbers in nu-
merical order followed by the letters in alphabetical order.
String lengths ranged from two to eight digits and letters,
and each trial presented three lists of the same string
length. Following standard scoring procedures as outlined
in the test manual [53], all seven trials (with three test
items per trial) (not including sample items) were given a
score of 0, 1, 2 or 3 (0 = fails all three trials, 1 = passes one
trial, 2 = passes two trials, 3 = passes all three trials). For
trials one and two, a score of 0 is given if a participant
provides an incorrect response, suggesting they did not
know the answer, or did not provide an answer within the
allocated time limit of 30 seconds. For trials three to ten,
credit is given for providing the correct letters in sequence
followed by the correct letters in sequence.
Psychometrically, the DSF and the DSB tasks of the
Digit Span subtest of the WAIS-IV [53] have been re-
ported to have good to excellent internal consistency reli-
ability (r = .81 for the DSF, and r = .93 for the DSB) for
older adult populations [54]. A confirmatory factor ana-
lysis of the WAIS-IV (model 5) revealed the Digit Span
subtest loaded onto the Working Memory factor .76,
suggesting the internal structure of the test captures the
content area reasonably well. Letter-number sequencing
from the WAIS-IV has been reported to be a reliable sub-
test (r = .88), and shown correlate better with the Digit
Span subtest than any other subtest of the WAIS-IV, indi-
cating it is indeed measuring memory [55].
Visual-spatial memory
The Benton Visual Retention Test (BVRT) [56] has been
employed to assess visual-spatial memory ability, visual-
motor construction ability and visual perception. Following
standard administrative and scoring procedure [56], partic-
ipants are shown 10 consecutive geometric designs for10 seconds each. Once the participant has had 10 seconds
viewing time, the design is hidden from view and they are
instructed to reproduce the design from memory by draw-
ing it on paper. Performance is scored as described in the
test manual [57] with two generated outcomes; 1. the total
number of correctly reproduced designs (0–10), and 2. the
total number of errors produced (0–10) that fall under six
categories: distortions, rotations, omissions, preservations,
size, and misplacements. Psychometrically, the BVRT has
been found to have good discriminant validity in the way it
distinguishes dementia from the effects of normal ageing
[58]. Moderate test-retest reliability for the Expected Num-
ber Correct Score (r = .78), along with a relatively low test-
retest reliability coefficient for the Error score (r = .57) has
been documented by prior research [59]. Alternate forms
of the BVRT (C, D and E) was used and counterbalanced
across participants over the three treatment arms.Speed of processing and visual-motor coordination
The Symbol Search and Coding core subtests from the
WAIS IV [53] were employed to measure processing speed.
The Symbol Search task involves participants scanning a
search group of symbols and indicating whether one of the
symbols in the target group matched. If a match was found,
the participants are instructed to draw a line through the
shape. Alternatively, if there was no match, the participant
is instructed to draw a line through the NO box. There are
60 items in this test, and participants are asked to complete
as many as possible within 120 seconds. Symbol Search
subtest has 60 items and participants are asked to complete
as many as possible within 120 seconds. The total raw score
for Symbol Search is calculated as standard [53] by sub-
tracting the total number of incorrect responses from the
total number of correct responses (maximum score = 60).
The Coding subtest has 135 items and requires partici-
pants to work within a time limit of 120 seconds. Partici-
pants are asked to copy symbols that are paired with
numbers in the correct order, as quickly as possible, with-
out making mistakes or skipping any. Participants are given
one point for each correctly drawn symbol made in the
allocated time limit of 120 seconds, not including sample
items. The total raw score for Coding is calculated as the
number of symbols correctly drawn within the 120 second
time limit (maximum score = 135). Numerous studies doc-
umented in the Technical and Interpretative Manual [53]
examining the psychometric properties of the WAIS IV’s
Symbol Search and Coding subtests, support the validity
and reliability of these measures. The test items within the
Coding and Symbol Search subtests correlate highly with
each other, and also load onto the “Processing Speed” factor
better than any other subtest in the WAIS-IV (i.e. Coding
.83 and Symbol Search .77) suggesting they adequately re-
flect the construct. Test-retest reliabilities reported by
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from .81 to .86 for Coding.Psychological well-being measures
Evidence from past research has indicated that depression
and anxiety [60] stress [61] and sleep [62] can all individu-
ally affect cognitive function. Thus, it was deemed import-
ant to determine whether any differences between the two
dietary groups could result from differences in these vari-
ables. Therefore, depression, anxiety, stress and sleep qual-
ity are assessed in the MedLey RCT to control for potential
confounding variables.
The following psychological well-being instruments are
utilised in the current study: 1. the Spielberger State-Trait
Anxiety Inventory Form Y (STAI-Y) [63] to measure symp-
toms of anxiety; 2. the Perceived Stress scale (PSS) [64] to
measure subjective stress levels; 3. The Centre for Epi-
demiological Studies Depression Scale (CES-D) [65] to
measure symptoms of depression; 4. a modified version of
the Leeds Sleep Evaluation Questionnaire (LSEQ) [66] to
assess the quality of their previous night’s sleep. These in-
struments were selected on the basis of their sound psy-
chometric properties and sensitivity with older adults. For
example, the STAI-Y has been found by Barnes, Harp and
Jung [67] to have excellent test-retest reliability (r = .88) at
multiple time points; evidence for excellent internal
consistency reliability (r = .91) has been found for the PSS
[68]; good internal consistency reliability (r = .88) has been
found for the CES-D [69]; and Parrott and Hindmarch [66]
have demonstrated with factor analysis, the four-factor
structure of the LSEQ were correlated.Cardiometabolic measures
Biomarkers for oxidative stress, inflammation, insulin
resistance, glucose regulation
Fasted 40 mL blood samples are collected from partici-
pants at each treatment arm (i.e. visit 1b, visit 2b, visit
3b) to assess hsCRP (biomarker of inflammation), F2-iso-
prostanes (biomarker of oxidative stress), plasma glucose
and insulin biomarker levels, for the ability to detect
metabolic abnormalities that may reflect insulin
resistance.
All blood samples are processed according to the
Australian standard operating procedures (SOPs).
Blood samples have been, and will continue to be taken
by venepuncture, by qualified personnel who have been
trained using standard aseptic techniques to avoid
cross-infection. Thereafter, blood samples are trans-
ported on ice to SA Pathology on Frome road in
Adelaide for analyses. F2-isoprostanes samples are
stored at -80C until sent to the University of Western
Australia (UWA) for the analysis of oxidative stress.Cerebral blood flow velocity - transcranial doppler (TCD)
Transcranial Doppler (TCD) ultrasound methods are
used to measure changes in middle cerebral artery blood
flow velocity (MCAV) at rest and in response to changes
in 5% CO2 inhalation (hypercapnia-induced cerebral
vasodilation), to determine the effects of dietary intake
of a MedDiet and HabDiet pattern on cerebral vascular
responsiveness to CO2. The examination takes place in a
temperature controlled room, where participants are sit-
ting in a comfortable upright position on a chair
throughout the entire assessment. A mouthpiece with a
two-way, non-rebreathing valve is fitted for each partici-
pant and a nose clip blocks inhalation through the nose.
Once secure, participants are asked to inhale a gas mix-
ture of 5% CO2/95% O2 for 2.5 minutes to initiate hy-
percapnia induced cerebrovascular dilatation. The left
transtemporal window (i.e. between the left ear and
alongside the zygomatic bone) is used for insonation of
the MCA. Assessments of the mean flow velocity in the
MCA is then recorded at a depth of 50 ± 10 mm for
each cardiac cycle throughout the entire 180 seconds,
and performed three times with a two minute rest
period, for optimum test reliability. A fitted spline curve
is used to smooth data collected during hypercapnia,
which provides the ability to determine the peak in-
crease in mean flow velocity. MCAV is expressed as a
percentage change from baseline [(peak mean flow vel-
ocity-baseline mean flow velocity) * 100/baseline mean
flow velocity].
Data screening and statistical analysis
Analyses will be conducted using SPSS Version 21.0 for
Windows (Chicago, IL, USA), with an alpha set at p < .05.
Following an “intention to treat” basis, descriptive statistics
will be performed for each testing phase with respect
to baseline characteristics. For categorical variables,
frequencies and percentages will be determined and
provided, along with the mean, standard deviation
(SD) and the standard error of the mean (SEM) statis-
tics for the continuous variables (or non-parametric
equivalents). Any non-normally distributed variables
will be transformed in accordance with standard meth-
odology to obtain a normal distribution of the data.
For the primary analysis, either a linear mixed model
(LMM) analysis, or a series of repeated measures
ANCOVA will be conducted to determine treatment ef-
fects in cognitive outcome as a function of allocated diet
for each participant over time, and to assess whether high
MedDiet intake over six months has a greater beneficial
effect on age-related cognitive performance for older
adults than HabDiet intake. For the secondary analysis, a
series of bivariate Pearson correlations and a multiple me-
diation model using a bootstrapping approach will be con-
ducted to assess whether the total and indirect effects of
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mediate the effect of diet (i.e. MedDiet and HabDiet) on
age-related cognitive performance. The covariates in-
cluded in the analysis will be organised into two models:
Model 1. (gender, age, education, presence of Apolipopro-
tein E-ɛ4 allele); Model 2. (self-rated depressive symptoms,
sleep quality, anxiety symptoms and stress levels).
Power and sample size calculation
Using the following standard conventions for estimat-
ing the sample size for a study with two equal groups
(i.e. Zα of 1.96 for 5% level of significance, Z1-β [1-β%
power] with β% of type II error [0.84 at 80% power],
r = n1/n2 ratio for equal sample size for 2 groups and
σ and d [the pooled standard deviation and difference
of means of 2 groups]) it was estimated that a total
sample size of 128 subjects (two groups of n = 64)
would provide 80% power to detect a significant effect
size of 0.5 (predicted change/SD of change, p < 0.05).
These values were based from previous research [70].
Such statistical power referred to here represents the
power required to detect a statistical difference be-
tween the treatment (MedDiet) and control (HabDiet)
groups in terms of mean performance or variance in
cognitive outcomes at an alpha level of .05, or put
another way, the probability of rejecting the null
hypothesis. This difference in change in cognitive out-
comes would represent a meaningful outcome, and
would be both clinically and theoretically relevant. To
account for potential participant withdrawal, we
aimed for an initial sample of 166 (an additional 38
volunteers, 19 per group) to allow for up to a 30%
subject withdrawal rate.
Discussion
The present protocol paper provides a detailed account of
the design implemented for a 6-month, randomised, con-
trolled, parallel group comparison intervention trial investi-
gating the therapeutic potential for a Mediterranean dietary
pattern to improve the cognitive performance and psycho-
logical well-being for healthy older adults aged 65 years and
above. Advantages of the present study are: 1. the use of
rigorous, randomised clinical intervention methodology,
providing a stringent way of determining whether cause-
effect relationships exists between the outcomes of interest,
2. investigating cognitively healthy older adults (≥65 years)
as the population of interest, 3. the extensive set of out-
comes investigated, including age-related cognitive, psycho-
logical well-being, cardiometabolic and genome health, and
potential mediating factors, 4. the use of a comprehensive,
psychometrically sound cognitive test battery, exclusively
developed for MedDiet-cognitive ageing research, enabling
assessment of a wide range of individual domains and
aspects of cognition sensitive to normal ageing and diet.To our knowledge, this will be the first empirical study
worldwide of this kind.
Undeniably, there is an urgent need for further empirical
research to uncover novel strategies that may minimise
such anticipated burden, promote healthy cognitive ageing,
and help enhance the overall quality of life for older adults,
dementia sufferers and their families and carers. Providing
justified evidence regarding the efficacy of a MedDiet ap-
proach to safely reduce cognitive decline, and promote suc-
cessful cognitive ageing could have great significance not
only theoretically and scientifically on a global interface, but
also for the overall health of society. Primarily, the out-
comes of this research may have the greatest relevance for
the estimated 524 million adults aged 65 years and older
worldwide, who are most at risk of pathologic cognitive
ageing [71], and also for the those among the Baby
Boomers generation who are presently approaching the
older age group (65 years and above). Furthermore, the im-
plications of this research may also have great economic
significance for society, Governments, and health care pro-
viders, if a potentially straightforward, safe, and inexpensive
approach to maintain cognitive health can be met through
modifying lifestyle and dietary behaviour.
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